Zawel Leigh's Form 4 filing
Cullinan Therapeutics, Inc. (CGEM) · filed Aug 11, 2021
- Accession no.
- 0000899243-21-032515
- Filed
- Aug 11, 2021
- Trade date
- Aug 9-10, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $752.9K. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0000899243-21-034314 (Aug 26, 2021). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zawel LeighCIK 0001837456 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2021 | Common Stock | SSaleDisposed | −19,504 | $26.52F1 | −$517,246.08 | 130,256 | Direct | |
| Aug 9, 2021 | Common Stock | SSaleDisposed | −1,700 | $27.11F2 | −$46,087 | 128,556 | Direct | |
| Aug 10, 2021 | Common Stock | SSaleDisposed | −1,906 | $26.50F3 | −$50,509 | 126,650 | Direct | |
| Aug 10, 2021 | Common Stock | SSaleDisposed | −3,191 | $27.34F4 | −$87,241.94 | 123,459 | Direct | |
| Aug 10, 2021 | Common Stock | SSaleDisposed | −1,817 | $28.49F5 | −$51,766.33 | 121,642 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Scientific Officer, Small Molecules